| Steatohepatitis: a tale of two “hits”? CP Day, OFW James Gastroenterology 114 (4), 842-845, 1998 | 5032 | 1998 |
| The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ... Hepatology 45 (4), 846-854, 2007 | 2124 | 2007 |
| QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. CP Day, JM McComb, RW Campbell Heart 63 (6), 342-344, 1990 | 1952 | 1990 |
| Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease G Targher, CP Day, E Bonora New England Journal of Medicine 363 (14), 1341-1350, 2010 | 1756 | 2010 |
| Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications GP Aithal, CP Day, PJL Kesteven, AK Daly The Lancet 353 (9154), 717-719, 1999 | 1574 | 1999 |
| Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients G Targher, L Bertolini, R Padovani, S Rodella, R Tessari, L Zenari, C Day, ... Diabetes care 30 (5), 1212-1218, 2007 | 1181 | 2007 |
| Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis QM Anstee, G Targher, CP Day Nature reviews Gastroenterology & hepatology 10 (6), 330, 2013 | 1177 | 2013 |
| The natural history of nonalcoholic fatty liver: a follow‐up study MR Teli, OFW James, AD Burt, MK Bennett, CP Day Hepatology 22 (6), 1714-1719, 1995 | 1147 | 1995 |
| HLA-B* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ... Nature genetics 41 (7), 816-819, 2009 | 951 | 2009 |
| Non-alcoholic fatty liver disease: the mist gradually clears NMW de Alwis, CP Day Journal of hepatology 48, S104-S112, 2008 | 906 | 2008 |
| EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease European Association for The Study of The Liver, ... Obesity facts 9 (2), 65-90, 2016 | 791 | 2016 |
| Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ... Hepatology 47 (2), 455-460, 2008 | 712 | 2008 |
| Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee Journal of hepatology 62 (5), 1148-1155, 2015 | 674 | 2015 |
| Pathogenesis of steatohepatitis CP Day Best practice & research Clinical gastroenterology 16 (5), 663-678, 2002 | 631 | 2002 |
| Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease S McPherson, SF Stewart, E Henderson, AD Burt, CP Day Gut 59 (9), 1265-1269, 2010 | 610 | 2010 |
| EASL clinical practical guidelines: management of alcoholic liver disease European Association For The Study Of The Liver Journal of hepatology 57 (2), 399-420, 2012 | 598 | 2012 |
| Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease A Lonardo, LE Adinolfi, P Loria, N Carulli, G Ruggiero, CP Day Gastroenterology 126 (2), 586-597, 2004 | 544 | 2004 |
| Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver MR Teli, CP Day, OFW James, AD Burt, MK Bennett The Lancet 346 (8981), 987-990, 1995 | 525 | 1995 |
| Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease L Valenti, A Al‐Serri, AK Daly, E Galmozzi, R Rametta, P Dongiovanni, ... Hepatology 51 (4), 1209-1217, 2010 | 523 | 2010 |
| From fat to inflammation CP Day Gastroenterology 130 (1), 207-210, 2006 | 487 | 2006 |
